HC Wainwright & Co. Maintains Buy on Crinetics Pharmaceuticals, Raises Price Target to $69
HC Wainwright & Co. Maintains Buy on Crinetics Pharmaceuticals, Raises Price Target to $69
HC Wainwright＆Co.維持對Crinetics Pharmaceuticals的買入評級，將目標股價提高至69美元。
HC Wainwright & Co. analyst Douglas Tsao maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy and raises the price target from $60 to $69.
HC韋恩伯格證券分析師Douglas Tsao 維持對Crinetics製藥（NASDAQ:CRNX）的買入評級，並將目標價從60美元上調至69美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間